International Clinical Neuroscience Journal

Vol. 7 No. 3 (2020)

Guillain–Barré Syndrome as a Neurological Complication of COVID-19 Infection: A Case Series and Review of the Literature

International Clinical Neuroscience Journal, Vol. 7 No. 3 (2020), 21 June 2020 , Page 156-161

Abstract

Background: The novel coronavirus (COVID-19) is a global pandemic. Although the main clinical manifestations of the COVID-19 infection has confined to the respiratory system, there is some evidence suggesting the neuro-invasive potential of the COVID-19. There are limited reports of Guillain–Barré syndrome (GBS) as a peripheral nervous system complication of COVID-19 infection.

Methods and results: We described four patients with COVID-19 infection who developed acute polyneuropathy with a final diagnosis of Guillain–Barré syndrome.

Conclusion: COVID-19 may have the potential to invade the peripheral nervous system. GBS, as one of the critical neurological complications of COVID-19, could be considered as a post-infectious event.

Keywords:
  • Novel corona-virus
  • COVID -19
  • neurological complication
  • Guillain–Barré syndrome
  • GBS

How to Cite

1.
Mozhdehipanah H, Paybast S, Gorji R. Guillain–Barré Syndrome as a Neurological Complication of COVID-19 Infection: A Case Series and Review of the Literature. Int Clin Neurosci J [Internet]. 2020 Jun. 21 [cited 2025 May 17];7(3):156-61. Available from: https://journals.sbmu.ac.ir/neuroscience/article/view/31031

References

Wang C, Horby P, Hayden F, Gao G. A novel coronavirus outbreak of global health concern. The Lancet. 2020;395.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.

Sheng J, Shao A. The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event. 1920.

Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A Literature Review. Journal of Clinical Neuroscience. 2020.

Sejvar J, Kohl K, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599-612.

Paybast S, Emami A, Koosha M, Baghalha F. Novel Coronavirus Disease (COVID-19) and Central Nervous System Complications: What Neurologist Need to Know. Acta Neurologica Taiwanica. 2020;29(1):24-31.

Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical profile of Guillain Barre syndrome. J Assoc Physicians India. 2013;61(3):168-72.

Nyati KK, Nyati R. Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update. BioMed research international. 2013;2013.

Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology. 2020;19(5):383-4.

Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. Journal of Clinical Neuroscience. 2020.

Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. IDCases. 2020:e00771.

Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré syndrome associated with SARS-CoV-2. New England Journal of Medicine. 2020.

McGonagle D, Sharif K, O'Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmunity reviews. 2020:102537.

  • Abstract Viewed: 745 times
  • PDF Downloaded: 894 times

Download Statastics